Dopaminergic response to graded dopamine concentration elicited by four amphetamine doses

We studied the metabolic responses to different DA concentrations elicited by four doses of D‐amphetamine (AMPH, 0, 0.25, 0.5, 1.0, or 3.0 mg/kg). We compared the degree of DA release (via microdialysis) with striatal cAMP activity and whole brain maps of cerebral blood volume (rCBV) changes (via pharmacological MRI, phMRI). Results: AMPH increased DA release in the caudate/putamen (CPu) and cAMP activity in the CPu, nucleus accumbens (NAc), and medial prefrontal cortex (mPFC) in a linear dose‐dependent manner (P < 0.0001). The cAMP data suggest that, postsynaptically, signal transduction induced by D1 receptor is stronger than that of D2 receptor at the higher doses (1–3 mg/kg). phMRI showed that, while higher doses of AMPH (3 mg/kg (n = 7) and 1 mg/kg (n = 6)) induced significant rCBV increases in the CPu and NAc, the degree of rCBV increase was much smaller with AMPH of 0.5 mg/kg (n = 6). In contrast, AMPH of 0.25 mg/kg (n = 8) induced significant rCBV decreases in the anteromedial CPu and NAc. The sign switch of rCBV in response to AMPH from low to high doses likely reflects the switching in the balance of D2/D3 stimulation vs. D1/D5 stimulation. In conclusion, degree of postsynaptic signal transduction is linearly correlated to the extracellular DA concentration. However, the presynaptic binding may dominate the overall DA innervation at the lower range of DA concentration. Synapse 63:764–772, 2009. © 2009 Wiley‐Liss, Inc.

[1]  B. Rosen,et al.  Dynamic imaging with lanthanide chelates in normal brain: Contrast due to magnetic susceptibility effects , 1988, Magnetic resonance in medicine.

[2]  B. Rosen,et al.  Mapping dopamine D2/D3 receptor function using pharmacological magnetic resonance imaging , 2005, Psychopharmacology.

[3]  A. Blamire,et al.  Region‐specific effects of a tyrosine‐free amino acid mixture on amphetamine‐induced changes in BOLD fMRI signal in the rat brain , 2007, Synapse.

[4]  B. MacVicar,et al.  Calcium transients in astrocyte endfeet cause cerebrovascular constrictions , 2004, Nature.

[5]  Ji-Kyung Choi,et al.  Brain hemodynamic changes mediated by dopamine receptors: Role of the cerebral microvasculature in dopamine-mediated neurovascular coupling , 2006, NeuroImage.

[6]  G. Paxinos,et al.  The Rat Brain in Stereotaxic Coordinates , 1983 .

[7]  B. Jenkins,et al.  Mapping Dopamine Function in Primates Using Pharmacologic Magnetic Resonance Imaging , 2004, The Journal of Neuroscience.

[8]  S. Strakowski,et al.  D3 dopamine receptor, behavioral sensitization, and psychosis , 2001, Neuroscience & Biobehavioral Reviews.

[9]  Angelo Bifone,et al.  In vivo mapping of functional connectivity in neurotransmitter systems using pharmacological MRI , 2007, NeuroImage.

[10]  A. L. Dixon,et al.  Dopamine antagonist modulation of amphetamine response as detected using pharmacological MRI , 2005, Neuropharmacology.

[11]  J. Mandeville,et al.  Vascular filters of functional MRI: Spatial localization using BOLD and CBV contrast , 1999, Magnetic resonance in medicine.

[12]  T. Takano,et al.  Signaling at the Gliovascular Interface , 2003, The Journal of Neuroscience.

[13]  Ji-Kyung Choi,et al.  Heterocyclic analogues of N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)arylcarboxamides with functionalized linking chains as novel dopamine D3 receptor ligands: potential substance abuse therapeutic agents. , 2007, Journal of medicinal chemistry.

[14]  D. Clark,et al.  Effects of low, autoreceptor selective doses of dopamine agonists on the discriminative cue and locomotor hyperactivity produced by d-amphetamine , 2005, Journal of Neural Transmission / General Section JNT.

[15]  K. Chergui,et al.  Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. , 1997, The Journal of pharmacology and experimental therapeutics.

[16]  R. Wightman,et al.  Real‐Time Monitoring of Electrically Stimulated Norepinephrine Release in Rat Thalamus: II. Modeling of Release and Reuptake Characteristics of Stimulated Norepinephrine Overflow , 1993, Journal of neurochemistry.

[17]  J. Bergman,et al.  Drug discrimination in methamphetamine-trained monkeys: agonist and antagonist effects of dopaminergic drugs. , 1998, The Journal of pharmacology and experimental therapeutics.

[18]  D. Cory-Slechta,et al.  Apparent mediation of the stimulus properties of a low dose of quinpirole by dopaminergic autoreceptors. , 1993, The Journal of pharmacology and experimental therapeutics.

[19]  Bruce G. Jenkins,et al.  Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[20]  P. Garris,et al.  Heterogeneity of evoked dopamine overflow wihin the striatal and striatoamygdaloid regions , 1994, Neuroscience.

[21]  P. Garris,et al.  Efflux of dopamine from the synaptic cleft in the nucleus accumbens of the rat brain , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[22]  R. Neubig,et al.  Regulators of G protein signaling & drugs of abuse. , 2005, Molecular interventions.

[23]  J. Mandeville,et al.  Improved mapping of pharmacologically induced neuronal activation using the IRON technique with superparamagnetic blood pool agents , 2001, Journal of magnetic resonance imaging : JMRI.

[24]  B R Rosen,et al.  Detection of dopaminergic neurotransmitter activity using pharmacologic MRI: Correlation with PET, microdialysis, and behavioral data , 1997, Magnetic resonance in medicine.

[25]  B. Rosen,et al.  Regional sensitivity and coupling of BOLD and CBV changes during stimulation of rat brain , 2001, Magnetic resonance in medicine.

[26]  M. Martres,et al.  The third dopamine receptor (D3) as a novel target for antipsychotics. , 1992, Biochemical pharmacology.

[27]  P. Greengard The neurobiology of slow synaptic transmission. , 2001, Science.

[28]  P. Goldman-Rakic,et al.  Dopaminergic regulation of cerebral cortical microcirculation , 1998, Nature Neuroscience.

[29]  D. Cory-Slechta,et al.  Functional alterations in dopamine systems assessed using drug discrimination procedures. , 1993, Neurotoxicology.

[30]  S. Laughlin,et al.  An Energy Budget for Signaling in the Grey Matter of the Brain , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[31]  B R Rosen,et al.  Detection of dopaminergic cell loss and neural transplantation using pharmacological MRI, PET and behavioral assessment. , 1999, Neuroreport.

[32]  R Weissleder,et al.  Monocrystalline iron oxide nanocompounds (MION): Physicochemical properties , 1993, Magnetic resonance in medicine.

[33]  M. C. Angulo,et al.  Neuron-to-astrocyte signaling is central to the dynamic control of brain microcirculation , 2003, Nature Neuroscience.

[34]  G. Crelier,et al.  Linear coupling between cerebral blood flow and oxygen consumption in activated human cortex. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[35]  Z. Kruk,et al.  Regional differences in evoked dopamine efflux in brain slices of rat anterior and posterior caudate putamen , 1992, Naunyn-Schmiedeberg's Archives of Pharmacology.

[36]  Ji-Kyung Choi,et al.  Exogenous contrast agent improves sensitivity of gradient‐echo functional magnetic resonance imaging at 9.4 T , 2004, Magnetic resonance in medicine.

[37]  M. Galloway,et al.  Dopamine D3-preferring ligands act at synthesis modulating autoreceptors. , 1995, The Journal of pharmacology and experimental therapeutics.

[38]  J. Mcculloch,et al.  Vasomotor responses of cerebral arterioles in situ to putative dopamine receptor agonists , 1985, British journal of pharmacology.